Diabetic Retinopathy Market Size, Cost Structure, Status and Forecasts to 2026

1
Diabetic Retinopathy Market to Reach USD 13.04
billion By 2026
2
Market Size USD 7.39 billion in 2018, Market
Growth CAGR of 7.3, Market Trends Product
Launches and Research for Advanced Tech
Developments
Market Summary
Based on current analysis, the global diabetic
retinopathy market was valued at USD 7.39 billion
in 2018 and is expected to reach USD 13.04
billion by 2026, at a CAGR of 7.3. Diabetic
retinopathy is a diabetes obstacle that affects
eyes. It's caused by damage to the blood vessels
of the light-sensitive tissue at the back of the
eye (retina). 

• Further key findings from the report suggest
• Asia-Pacific regional segment of the diabetic
  retinopathy market is expected to register itself
  as highest growing segment during the forecasted
  period, at a CAGR of 8.3 owing it to the
  qualitative as well as quantitative market
  potential offered in developing nations such as
  China India
• Non-proliferative diabetic retinopathy has
  registered highest CAGR of 7.5 and is successful
  in dominating the market with market share of
  56. The most common reason for blindness in
  people suffering from diabetes is
  non-proliferative
• According to the estimates of the screening
  conducted by the All India Ophthalmological
  Society, the prevalence of diabetic retinopathy
  in the data set collected by them was
  approximately calculated to 21.7

www.reportsanddata.com
3
Market Summary
Key Players
Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd.,
Regeneron Pharmaceuticals Inc., Novartis AG,
Valeant Pharmaceuticals International Inc.,
Abbott Laboratories Ltd., Alimera Sciences Inc.,
AmPio Pharmaceuticals Inc., Bausch Lomb Inc.,
Boehringer Ingelheim GmbH, iCo Therapeutics Inc.,
Lupin Ltd., PAREXEL International Corp., Quark
Pharmaceuticals Inc., Thrombogenic NV, and
Vitreoretinal Technologies Inc
Segmentation
Type (Revenue in USD Million 20162026) Prolifera
tive diabetic retinopathy Non-proliferative
diabetic retinopathy Mild Moderate Severe Manageme
nt (Revenue in USD Million 20162026) Anti-VEGF I
ntraocular steroid injection Laser
surgery Vitrectomy
To look at the PDF Sample Report and get 30
minutes of a free consultation _at_https//www.report
sanddata.com/sample-enquiry-form/1484
www.reportsanddata.com
4
Market Summary

• Distribution channel (Revenue in USD Million
  20162026)
• Eye clinics
• Hospital and pharmacies
• Ambulatory surgical centers
• Other
• Regional Outlook (Revenue in USD Million
  20162026)
• North America (United States, Canada, and Mexico)
• Europe (Germany, France, UK, Russia, and Italy)
• Asia-Pacific (China, Japan, Korea, India, and
  Southeast Asia)
• South America (Brazil, Argentina, Colombia, etc.)
• Middle East and Africa (Saudi Arabia, UAE, Egypt,
  Nigeria, and South Africa)

Grab Your Report at an Impressive Discount!
Please Click Here _at_https//www.reportsanddata.co
m/discount-enquiry-form/1484
www.reportsanddata.com
5
The report emphasizes the following key
questions
Q.1.What are the most lucrative and promising
growth prospects for the market? Q.2.Which
sectors are expected to deliver a high growth
rate and which industry aspects come into play in
this advancement? Q.3.Which geographies are
estimated to exhibit the highest growth and the
underlying causes? Q.4.Which factors are
impacting the future of the market and what are
the driving factors? Q.5.What are the hurdles
and challenges curtailing the industrys growth
in the forecast period?
www.reportsanddata.com
6
About Us
Reports and Data is a market research and
consulting company that provides syndicated
research reports, customized research reports,
and consulting services. Our solutions purely
focus on your purpose to locate, target and
analyze consumer behavior shifts across
demographics, across industries and help clients
make a smarter business decision. We offer market
intelligence studies ensuring relevant and
fact-based research across a multiple industries
including Healthcare, Technology, Chemicals,
Power, and Energy. We consistently update our
research offerings to ensure our clients are
aware about the latest trends existent in the
market. Reports and Data has a strong base of
experienced analysts from varied areas of
expertise.
Contact Us John Watson Head of Business
Development Reports And Data Web
www.reportsanddata.com Direct Line
1-212-710-1370 E-mail sales_at_reportsanddata.com